CytRx to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CytRx Corporation (OTCQB: CYTR) announced that its CEO, Steven A. Kriegsman, will participate in two upcoming conferences. First, he will deliver a virtual presentation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021, available for on-demand viewing. Following this, he will present at the Virtual 33rd Annual ROTH Conference from March 15-17, 2021, with access starting on March 5, 2021 on CytRx's website. CytRx focuses on developing therapeutics for cancer and neurodegenerative diseases.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to participate in the following upcoming conferences:

• H.C. Wainwright Global Life Sciences Conference: March 9-10, 2021
  • Mr. Kriegsman will deliver a virtual presentation that will be available to conference participants on-demand beginning March 9, 2021.

• Virtual 33^rd Annual ROTH Conference: March 15-17, 2021
  • Mr. Kriegsman will deliver a virtual presentation that may be accessed on the News and Events page of the CytRx website beginning March 5, 2021.

About CytRx Corporation

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). CytRx Corporation’s website is www.cytrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005178/en/

FAQ

When will CytRx CEO Steven A. Kriegsman speak at the H.C. Wainwright Global Life Sciences Conference?

Steven A. Kriegsman will speak at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

What date is the Virtual 33rd Annual ROTH Conference where CytRx will present?

The Virtual 33rd Annual ROTH Conference is scheduled for March 15-17, 2021.

Where can I watch CytRx's CEO presentation for the ROTH Conference?

The presentation for the ROTH Conference will be available on CytRx's News and Events page starting March 5, 2021.

What is the primary focus of CytRx Corporation?

CytRx Corporation specializes in developing therapeutics for oncology and neurodegenerative diseases.

What is aldoxorubicin and what role does it play in CytRx's portfolio?

Aldoxorubicin is a drug conjugate developed by CytRx, designed to improve treatment for cancer, and is currently out-licensed to ImmunityBio.